Physicians’ Prescription Behaviour: An Empirical Study of in the Context of Critical Diseases
DOI:
https://doi.org/10.61841/hzm3k934Keywords:
Physician prescription behavior, critical diseases, patient-related factors, disease-related factors, pharmaceutical company-related factors, physician-related factors, medical educationAbstract
This study aims to investigate the various parameters that cause several inclinations physicians' prescription behavior in the context of critical diseases. Patient-related factors, such as patients' socioeconomic status and insurance coverage significantly influence physicians' prescription behavior. Additionally, disease-related factors, such as the severity of the disease and the complexity of the treatment regimen also impact physicians' prescription behavior. Pharmaceutical company-related factors, such as drug marketing and promotional activities, also play a crucial role in influencing physicians' prescription behavior. Finally, physicianrelated factors, such as their experience and medical education, were found to influence prescription behavior. Overall, the study provides valuable insights into the complex nature of physicians' prescription behavior in the context of critical diseases, highlighting the importance of various factors that influence this behavior. 247 people were surveyed to know the factors influencing prescription behaviour of physicians. These findings have important implications for healthcare policymakers, medical professionals, and pharmaceutical companies, as they provide insight into how best to address the various factors that influence prescription behavior and optimize treatment outcomes for critical diseases.
Downloads
References
• Balasubramanian, N., Ganeshkumar, P., & Kattimani, S. (2016). Physician-industry
interaction: Healthcare professionals’ perception of conflicts of interest in India. Indian
Journal of Medical Ethics, 1(2), 66-71.
• Chatterjee, P., Biswas, T., & Datta, A. (2018). Promotion and prescription practices of
pharmaceutical drugs: A study among physicians in a tertiary-care hospital in Kolkata.
Journal of Education and Health Promotion, 7, 54.
• Dellit, T. H., Owens, R. C., McGowan Jr, J. E., Gerding, D. N., Weinstein, R. A., Burke,
J. P., ... & IDSA/SIS/APIC Guidelines Committee (2007). Infectious Diseases Society
of America and the Society for Healthcare Epidemiology of America guidelines for
developing an institutional program to enhance antimicrobial stewardship. Clinical
Infectious Diseases, 44(2), 159-177.
• Hassali, M. A., Kong, D. C. M., & Stewart, K. (2012). Generic medicines: Perceptions
of physicians in selected hospitals in Penang, Malaysia, and their prescribing patterns.
The Australasian Medical Journal, 5(8), 436-442.
• Kesselheim, A. S., Misono, A. S., Lee, J. L., Stedman, M. R., Brookhart, M. A.,
Choudhry, N. K., & Shrank, W. H. (2016). Clinical equivalence of generic and brandname drugs used in cardiovascular disease: A systematic review and meta-analysis.
Journal of the American Medical Association, 315(16), 1720-1730.
• Knapp, H., Anzueto, A., Criner, G. J., Kelsen, S., & Martinez, F. J. (2014). Physician
perspectives on the management of COPD. International journal of chronic obstructive
pulmonary disease, 9, 1269–1282. https://doi.org/10.2147/COPD.S66725
• Mashamba-Thompson, T. P., Sartorius, B., Sartorius, K., & Choonara, Y. (2017).
Patients’ perspectives on generic medicines in South Africa: A qualitative study using
focus groups and semi-structured interviews among human immunodeficiency virus
infected adults. Journal of Pharmaceutical Policy and Practice, 10(1), 24.
https://doi.org/10.1186/s40545-017-0114-4
• Norris, S. L., Holmer, H. K., Ogden, L. A., Burda, B. U., Fu, R., & Bero, L. A. (2013).
Characteristics of physicians receiving large payments from pharmaceutical companies
and the accuracy of their disclosures. JAMA, 309(4), 357-359.
https://doi.org/10.1001/jama.2012.116585
• Persaud, N., Lee, T., Ahmad, M., Li, W., Taglione, M. S., & Jain, S. (2012). Informed
public opinion on the use of generic drugs. Canadian Family Physician, 58(8), e460-
e466. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419239/
• Shrank, W. H., Cox, E. R., Fischer, M. A., Mehta, J., Choudhry, N. K., & Gleason, P.
P. (2011). Patients’ perceptions of generic medications. Health Affairs, 30(11), 2151-
2157. https://doi.org/10.1377/hlthaff.2011.0290
• Shrank, W. H., Liberman, J. N., Fischer, M. A., Girdish, C., Brennan, T. A., &
Choudhry, N. K. (2009). Physician perceptions about generic drugs. Annals of
Pharmacotherapy, 43(6), 1006-1011. https://doi.org/10.1345/aph.1L566
• Spurling, G. K., Mansfield, P. R., Montgomery, B. D., & Lexchin, J. (2010).
Information from pharmaceutical companies and the quality, quantity, and cost of
physicians' prescribing: a systematic review. PLoS medicine, 7(10), e1000352.
https://doi.org/10.1371/journal.pmed.1000352
• Steinman, M. A., Shlipak, M. G., McPhee, S. J., & Ofman, J. J. (2006). Narrative
review: The promotion of gabapentin: An analysis of internal industry documents.
Annals of Internal Medicine, 145(4), 284-293
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
